PVR and Nectin-2 Blockade Reactivates Macrophage Anti-Tumor Functions in Cervical Cancer
Despite vaccination programs, cervical cancer remains a major health burden. Anti-PD-1 immunotherapy with pembrolizumab improved progression-free survival from 20% to 50% in advanced disease — yet many patients remain resistant, calling for new immune checkpoint targets. One promising candidate is the TIGIT–PVRL axis: TIGIT, expressed by regulatory and exhausted T cells, binds its ligands PVR and Nectin-2 to maintain immunosuppression in the tumor microenvironment.
In a new study from the Cancer Research Center of Marseille (Gorvel et al., bioRxiv preprint), researchers explored the other side of this axis — the myeloid compartment. Showing that PVR and Nectin-2 are highly expressed on tumor cells and tumor-associated macrophages (TAMs) across cervical tumor subsets, they tested whether blocking these ligands could lift immunosuppression, combining CyTOF immunophenotyping, high-throughput confocal imaging, 3D co-culture models, and autologous tumor–PBMC co-cultures under flow using MIVO® millifluidics.
Key Findings
- Macrophage repolarization. Anti-PVR and anti-Nectin-2 antibodies shifted macrophages from an immunosuppressive, M2-like profile towards an inflammatory phenotype.
- Phagocytosis restored. PVR — described as a secondary “don’t eat me” signal — was shown to sustain tumor escape: its blockade restored macrophage-mediated phagocytosis of cervical tumor cells.
- Tumor growth controlled in 2D and 3D. The dual blockade reduced tumor growth in co-culture models, suggesting that complete blockade of TIGIT–ligand interactions reinvigorates anti-tumor immunity.
- Immune recruitment enhanced under flow. In a preclinical autologous model pairing patient cervical tumor cells with circulating PBMCs in the MIVO® system, anti-PVR/Nectin-2 treatment improved immune cell recruitment towards the tumor.
Take-Home Message
This study provides a first proof of concept that targeting the TIGIT–PVRL axis from the myeloid side — through dual PVR/Nectin-2 blockade — restores macrophage inflammatory functions and cervical tumor growth control in vitro and ex vivo. Such macrophage-targeting approaches could complement T cell-directed immunotherapies, and complex millifluidic co-culture models offer a relevant platform to test them with human autologous cells.
Note: this work is a preprint and has not yet been peer-reviewed.
Reference: Diallo OM, Boucherit N, Fernez T, Barry AO, Billion E, Rouvière MS, et al. PVR and Nectin-2 blockade trigger macrophage anti-tumor functions, promote immune cell recruitment and prevent cervical tumor growth. bioRxiv. 2026. https://doi.org/10.64898/2026.01.30.702794
All Resources
Never stop learning!
Check publications from the team, protocols, and useful information to boost your research and get into organ on chip technology!

